Weight-Loss drug investigated as potential kidney protector

NCT ID NCT05536804

Summary

This study is investigating whether the medication tirzepatide, which is approved for weight loss and diabetes, can improve kidney health in people who are overweight or obese and have chronic kidney disease. Researchers will use special MRI scans to see if the drug increases oxygen levels in the kidneys and reduces kidney fat. The goal is to see if this medication can help control kidney disease progression in this high-risk group.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Aarhus Universitetshospital, Skejby

    Aarhus, 8200, Denmark

  • American Health Network of Indiana, LLC - Avon

    Avon, Indiana, 46123, United States

  • American Health Network of Indiana, LLC - Greenfield

    Greenfield, Indiana, 46140, United States

  • American Health Network of Indiana, LLC - Muncie

    Muncie, Indiana, 47304, United States

  • Amsterdam UMC, locatie VUmc

    Amsterdam, 1081 HV, Netherlands

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

    Troy, Michigan, 48098, United States

  • Caimed Investigacion En Salud S.A. de C.V.

    Mexico City, 06760, Mexico

  • Centre intégré universitaire de santé et de services sociaux de l'Estrie Centre Hospitalier Universitaire -T

    Sherbrooke, J1H 5N4, Canada

  • Centro de Investigación y Gastroenterología

    Cuauhtémoc, 06700, Mexico

  • Fadia El Boreky Medicine

    Waterloo, N2J 1C4, Canada

  • Grupo Medico Camino Sc

    Mexico City, 03310, Mexico

  • Health Pharma Professional Research S.A. de C.V:

    Mexico City, 03100, Mexico

  • Indiana University Health University Hospital

    Indianapolis, Indiana, 46202, United States

  • Instituto Nacional de Cardiologia Ignacio Chavez

    México, 14080, Mexico

  • Investigación Nefrológica

    Cuernavaca, 62448, Mexico

  • Kidney Associates of Colorado

    Denver, Colorado, 80210, United States

  • Klinik Hietzing

    Vienna, 1130, Austria

  • Klinik Landstraße

    Vienna, 1030, Austria

  • LMC Clinical Research Inc. (Barrie)

    Barrie, L4N 7L3, Canada

  • LMC Clinical Research Inc. (Thornhill)

    Concord, L4K 4M2, Canada

  • Providence Medical Research Center - Spokane

    Spokane, Washington, 99204, United States

  • Toronto General Hospital

    Toronto, M5G 2C4, Canada

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, 80045, United States

  • University of Washington Medical Center - Montlake

    Seattle, Washington, 98195, United States

  • Valley Clinical Trials, Inc.

    Northridge, California, 91325, United States

  • Zentrum für klinische Studien Dr Hanusch Gmbh

    Vienna, 1060, Austria

  • Ziekenhuisgroep Twente, locatie Almelo

    Almelo, 7609 PP, Netherlands

Conditions

Explore the condition pages connected to this study.